Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View moreNuclear Medicine Treatment Cures Lethal Form of Ovarian Cancer in Preclinical Setting
Mayo Clinic and GE HealthCare Collaborate to Drive Innovation in Medical Imaging and Theranostics
First patient dosed in Phase Ib study in small cell lung cancer
BOP preliminary trial results presented at EANM 2023 conference
Emerging PSMA PET Agent May Offer Improved Detection of Prostate Cancer
Shine Technologies and Curadh MTR Announce Expanded Strategic Partnership to Advance Cancer Therapies using Terbium and Lutetium